Nuo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 19, 2024
AURXStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
For the Years Ended December 31, 2023 and 2022
| Common Stock | |||||
|---|---|---|---|---|---|
| Shares | Amount (par $0.0001) | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | |
| Balance, December 31, 2021 | 37,124,205 | $3,713 | $24,382,195 | $(23,593,069) | $792,839 |
| Share-based compensation expense | - | - | 9,145 | - | 9,145 |
| Issuance of options to settle related party compensation liabilities | - | - | 103,333 | - | 103,333 |
| Issuance of common shares | 3,957,757 | 396 | 3,957,361 | - | 3,957,757 |
| Issuance of common shares, participation right and contingent warrant | 500,000 | 50 | 499,950 | - | 500,000 |
| Exercise of warrants | 217,054 | 21 | (21) | - | - |
| Net loss | - | - | - | (3,171,736) | (3,171,736) |
| Balance, December 31, 2022 | 41,799,016 | 4,180 | 28,951,963 | (26,764,805) | 2,191,338 |
| Share-based compensation expense | - | - | 21,746 | - | 21,746 |
| Issuance of common shares | 2,422,500 | 244 | 1,997,256 | - | 1,997,500 |
| Net loss | - | - | - | (3,171,436) | (3,171,436) |
| Balance, December 31, 2023 | 44,241,516 | $4,424 | $30,970,965 | $(29,936,241) | $1,039,148 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.